CADTH Canadian Drug Expert Committee recommendation. indication : treatment of neovascular (wet) age-related macular degeneration (nAMD). Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) :
Brolucizumab has a Health Canada indication for the treatment of nAMD. Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment directed against human VEGF. It is available as a single-use pre-filled syringe for intravitreal injection and the Health Canada-approved dose is 6...
Saved in:
| Online Access: |
Full text |
|---|---|
| Corporate Author: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2020
|
| Edition: | Version: 1. |
| Series: | Common drug review clinical review report.
|
| Subjects: |
| Summary: | Brolucizumab has a Health Canada indication for the treatment of nAMD. Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment directed against human VEGF. It is available as a single-use pre-filled syringe for intravitreal injection and the Health Canada-approved dose is 6 mg (0.05 mL) administered by intravitreal injection every four weeks for the first three doses, after which it can be given as one injection every 12 weeks in patients without disease activity or one injection every eight weeks in patients with disease activity, based on the physician assessment. |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 online resource (1 PDF file (8 pages)). |
| Source of Description, Etc. Note: | Description based on online resource; title from PDF title page (viewed May 11, 2021). |
| Funding Information Note: | Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. |
